Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
- 16 December 2014
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 21 (6) , 773-790
Abstract
Recent findings indicate cardiovascular disease (CVD) risk is best predicted by asleep systolic blood pressure (SBP), and lowering it by scheduling ≥1 conventional long-acting hypertension medications, alone or in combination, at bedtime significantly lessens vascular-associated risks. Some 20 years ago, four controlled-onset extended-release drug-delivery systems incorporating a calcium channel or β-blocker, with the treatment goal specifically being attenuation of morning rather than asleep BP, were conceived as one type of bedtime hypertension chronotherapy. However, the CONVINCE outcomes trial failed to substantiate the merit of targeting morning and daytime BP to decrease CVD risk. The HOPE trial, entailing bedtime ramipril treatment for high CVD risk patients, showed substantial reduction of vascular-related events, theorized as the beneficial treatment-time-dependent strong asleep BP lowering. The MAPEC trial was the first prospective randomized treatment-time outcomes investigation to test the worthiness of bedtime hypertension chronotherapy entailing ≥1 conventional long-acting medications (BTCT), in comparison to the conventional morning-time therapeutic scheme for all medications (CMTT), to normalize asleep BP and diminish CVD risk. BTCT compared to CMTT significantly better lowered asleep BP and most importantly major CVD-associated morbidity and mortality, including myocardial infarction and ischemic and hemorrhagic stroke, by ~60%. CVD risk reduction was strongest when the BTCT included an angiotensin receptor blocker. The HOPE and MAPEC trials provide positive evidence of very significant CVD risk reduction by a BTCT strategy that specifically targets normalization of asleep BP, evidence that awaits conformation by the ongoing Hygia and other outcomes trials.Keywords
This publication has 106 references indexed in Scilit:
- Corrected Data in Table and Clarification of RationaleJAMA, 2014
- Decreasing Sleep-Time Blood Pressure Determined by Ambulatory Monitoring Reduces Cardiovascular RiskJACC, 2011
- The Primary Benefits of Angiotensin-Converting Enzyme Inhibition on Cardiac Remodeling Occur During Sleep Time in Murine Pressure Overload HypertrophyJACC, 2011
- Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertensionClinical and Experimental Nephrology, 2009
- Importance of Aggressive Blood Pressure Lowering When It May Matter MostThe American Journal of Cardiology, 2007
- Chronotherapy of hypertension: Administration-time-dependent effects of treatment on the circadian pattern of blood pressureAdvanced Drug Delivery Reviews, 2007
- Relationship Between Diurnal Blood Pressure Variation and Diurnal Blood Glucose Levels in Type 2 Diabetic PatientsAmerican Journal of Hypertension, 2007
- Captopril Administered at Night Restores the Diurnal Blood Pessure Rhythm in Adequately Controlled, Nondipping HypertensivesCardiovascular Drugs and Therapy, 2005
- Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure productAmerican Heart Journal, 2004
- Circadian variation of plaque rupture in acute myocardial infarctionThe American Journal of Cardiology, 2004